Herpes Simplex Virus Type 2 Acquisition Among HIV-1-Infected Adults Treated With Tenofovir Disoproxyl Fumarate as Part of Combination Antiretroviral Therapy: Results From the ACTG A5175 PEARLS Study

Connie Celum; Ting Hong; Anne Cent; Deborah Donnell; Rhoda Morrow; Jared M Baeten; Cynthia Firnhaber; Beatriz Grinsztejn; Mina C Hosseinipour; Umesh Lalloo; Mulinda Nyirenda; Cynthia Riviere; Jorge Sanchez; Breno Santos; Khuanchai Supparatpinyo; James Hakim; N Kumarasamy; Thomas B Campbell; ACTG PEARLS/A5175 Team

doi:10.1093/infdis/jix029

Herpes Simplex Virus Type 2 Acquisition Among HIV-1-Infected Adults Treated With Tenofovir Disoproxyl Fumarate as Part of Combination Antiretroviral Therapy: Results From the ACTG A5175 PEARLS Study

J Infect Dis. 2017 Mar 15;215(6):907-910. doi: 10.1093/infdis/jix029.

Authors

Connie Celum^{1

2

3}, Ting Hong¹, Anne Cent⁴, Deborah Donnell^{1

5}, Rhoda Morrow^{4

5}, Jared M Baeten^{1

2

3}, Cynthia Firnhaber⁶, Beatriz Grinsztejn⁷, Mina C Hosseinipour⁸, Umesh Lalloo⁹, Mulinda Nyirenda¹⁰, Cynthia Riviere¹¹, Jorge Sanchez¹², Breno Santos¹³, Khuanchai Supparatpinyo¹⁴, James Hakim¹⁵, N Kumarasamy¹⁶, Thomas B Campbell¹⁷; ACTG PEARLS/A5175 Team

Affiliations

¹ Department of Global Health, University of Washington , Seattle, Washington, USA.
² Department of Medicine, University of Washington , Seattle, Washington, USA.
³ Department of Epidemiology, University of Washington, Seattle, Washington, USA.
⁴ Laboratory Medicine, University of Washington, USA.
⁵ Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
⁶ Clinical HIV Research Unit, Department of Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
⁷ Evandro Chagas Clinical Research Institute, FIOCRUZ, Rio de Janeiro, Brazil.
⁸ Kamuzu Central Hospital, Lilongwe, Malawi.
⁹ Nelson R. Mandela School of Medicine, Durban, South Africa.
¹⁰ Department of Medicine, College of Medicine, Blantyre, Malawi.
¹¹ Institut Nacional de laboratoire et de Recherches, Port-au-Prince, Haiti.
¹² Asociación Civil Impacta Salud y Educación, Lima, Peru.
¹³ Servico de Infectology, Hospital Nossa Senhora da Conceicao -GHC, Porto Alegre, Brazil.
¹⁴ Department of Medicine, Research Institute for Health Sciences, Chiang Mai University, Thailand.
¹⁵ University of Zimbabwe College of Health Sciences, Harare, Zimbabwe.
¹⁶ YRG Centre for AIDS Research and Education, Chennai, India.
¹⁷ Department of Medicine, University of Colorado School of Medicine, Aurora, USA.

Abstract

Objective: Tenofovir disoproxyl fumarate (TDF) disoproxyl fumarate (TDF) has in vitro activity against herpes simplex virus type 2 (HSV-2) and reduced HSV-2 acquisition as preexposure prophylaxis. Whether TDF-containing antiretroviral therapy (ART) reduces HSV-2 acquisition is unknown.

Design: Secondary analysis of AIDS Clinical Trials Group A5175, a randomized, open-label study of 3 ART regimens among 1571 participants.

Methods: HSV-2 serostatus was assessed at baseline, at study exit, and before a change in ART regimen.

Results: Of 365 HSV-2-seronegative persons, 68 acquired HSV-2, with 24 receiving TDF-containing ART and 44 receiving ART without TDF (HSV-2 seroconversion incidence, 6.42 and 6.63 cases/100 person-years, respectively; hazard ratio, 0.89; 95% confidence interval, .55-1.44).

Conclusions: HSV-2 acquisition was not reduced in HIV-infected, HSV-2-uninfected persons during TDF-containing ART.

Keywords: Africa; HIV-1; HSV-2; antiretroviral therapy; prevention; tenofovir.

Publication types

Randomized Controlled Trial

MeSH terms

Adolescent
Adult
Antiviral Agents / therapeutic use*
Female
HIV Infections / complications*
HIV Infections / drug therapy
HIV-1 / drug effects
Herpes Simplex / prevention & control*
Herpesvirus 2, Human / drug effects*
Humans
International Cooperation
Male
Medication Adherence
Middle Aged
Pre-Exposure Prophylaxis*
Proportional Hazards Models
Seroconversion
Tenofovir / therapeutic use*
Young Adult

Substances

Antiviral Agents
Tenofovir

Abstract

Publication types

MeSH terms

Substances

Grants and funding